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Kidney Dysfunction Impact on 
White Matter Hyperintensity 
Volume in Neurologically Healthy 
Adults
sang Hyuck Kim1, Jae Moon Yun2, su-Min Jeong2, shinhye Kim  3, tae Gon Yoo2, Ji eun Lee2, 
Jae-sung Lim4, Han-Yeoung Jeong5, Ki-Woong Nam  5, Hyung-Min Kwon5,6 & Jin-Ho park2,7
the detrimental outcomes of white matter hyperintensity (WMH) are known to be proportional to 
WMH volume. this study aimed to evaluate the association between kidney dysfunction and white 
matter hyperintensity (WMH) volume. A total of 2,203 subjects who underwent brain magnetic 
resonance imaging (MRI) as part of a screening health check-up was included in this study. WMH was 
defined as hyperintensity signals without cavity formation in the white matter on fluid-attenuated 
inversion recovery images. WMH volume was measured quantitatively, and data were normalized by 
square root transformation prior to analysis. Mean age of the subjects was 56.9 years and mean WMH 
volume was 2.7 cm3. Mean estimated glomerular filtration rate (eGFR) level was 78.0 ml/min/1.73 m2, 
and 172 subjects (7.8%) were diagnosed with moderate-to-severe kidney dysfunction (eGFR < 60). 
Mean Urine albumin-to-creatinine ratio (UACR) was 0.02, and 166 subjects showed significant 
albuminuria (UACR ≥ 0.03). Multivariate analyses showed that each of UACR, significant albuminuria, 
and moderate-to-severe kidney dysfunction was significantly associated with increased WMH 
volume (all p < 0.05). When we considered significant albuminuria and moderate-to-severe kidney 
dysfunction simultaneously, subjects with both significant albuminuria and moderate-to-severe kidney 
dysfunction had more than twice the WMH volume as did those in the other groups (all p < 0.05). Kidney 
dysfunction, defined by albuminuria and eGFR, was independently associated with WMH volume. Risk 
factors related to WMH and its detrimental outcomes should be strictly modified in subjects with kidney 
dysfunction, especially in those with both albuminuria and a reduced eGFR.
White matter hyperintensity (WMH) is a frequently encountered abnormal finding in brain magnetic resonance 
imaging (MRI) studies. This anomaly is more frequently observed in the elderly population and is regarded as 
a non-specific finding associated with the aging process1,2. However, mounting clinical evidence supports the 
fact that an advanced degree of WMH is associated with several physical dysfunctions and clinically detrimental 
outcomes2–4. Research studies have shown that WMH is associated with cognitive impairment, gait disturbance, 
mood change, functional decline, and urinary incontinence2. In addition, WMH increases the risk of stroke and 
stroke-related complications, including vascular dementia, and bleeding after thrombolysis2–4. Consequently, due 
to these clinical implications, WMH is regarded as a potential surrogate marker of overt stroke3.
Since the microvascular structures of both the kidney and the brain are similar, it has been suggested 
that markers for chronic kidney disease could be predictors of cerebral vascular diseases including WMH5,6. 
Considering that the detrimental outcomes of WMH are known to be proportional to WMH volume2, 
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quantitative volumetric assessment is critical in evaluating the association between markers for kidney dysfunc-
tion and WMH. In addition to the shortage of studies targeting the association between kidney dysfunction and 
WMH volume, the volumetric complexity and characteristics of WMH itself can cause methodological limita-
tions, such as using the WMH grade instead of volume itself7,8, and the inappropriate treatment of a zero value for 
WMH volume during logarithmic transformation9,10.
This study aimed to assess the association between kidney dysfunction, as defined by urine 
albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and quantitative WMH vol-
ume, as measured by a semi-automated technique.
Methods
Subjects and variables. This study included subjects aged 40 years or older who, at their own expense, 
underwent routine health check-ups including brain MRI at Seoul National University Hospital Health 
Promotion Center between January 2006 and December 2013. Upon their initial visit, subjects were asked to 
complete detailed questionnaires regarding their sociodemographic background, lifestyle, and medical history. 
Subjects then consulted with a trained family physician with regard to their past medical histories and current 
medications. In terms of smoking habit, subjects were categorized as (1) non- or former smoker, or (2) cur-
rent smoker. We also identified subjects who were taking anti-hypertensive, anti-diabetic, anti-dyslipidemic, or 
anti-coagulation/anti-platelet drugs. The screening program included anthropometric assessment, blood pres-
sure, electrocardiogram, blood sampling for metabolic and biochemical traits after overnight fasting, urinary 
tests, and brain MRI. Hypertension was defined as when subjects were taking antihypertensive drugs or when 
systolic blood pressure (SBP) ≥ 140 mmHg, or when diastolic blood pressure (DBP) ≥ 90 mmHg. Diabetes was 
defined when subjects were taking antidiabetic drugs or had a fasting blood glucose level ≥126 mg/dL or an 
HbA1c ≥6.5%. Dyslipidemia was defined when subjects were taking lipid lowering drugs or when their total 
cholesterol level was ≥240 mg/dL. The detailed MRI protocol is described elsewhere11.
A total of 3,131 subjects, aged 40 years or more, underwent brain MRI as part of their routine health screening 
check-ups. Of these, 925 subjects were excluded due to missing urinary albumin and creatinine levels. We also 
excluded 3 subjects who had a previous history of stroke. Finally, a total of 2,203 subjects were included in our 
analysis.
This study was approved by the institutional review board at Seoul National University Hospital. (IRB No. 
H-1604-072-754). Informed consent was exempted by the IRB due to anonymous information collection and 
retrospective study design. All methods were performed in accordance with relevant guidelines and regulations.
Assessment of the volume of white matter hyperintensity. Hyperintensity signals without cavity 
formation (in other words, signal which differed from that of the cerebrospinal fluid)that appeared in a variety of 
different sizes in the white matter upon fluid-attenuated inversion recovery images from brain MRI were defined 
as WMH.1Lesions in the subcortical grey matter or brainstem were not included in this category. The WMH vol-
ume (cm3) of each subject was calculated using a semi-automated technique using MRIcro software (http://www.
mricro.com). Semi-automated volumetric WMH measurements are more objective and reliable than qualitative 
scales. In addition, this method overcomes the shortcoming of visual ratings, such as ceiling effects. Scans were 
converted from DICOM to Analyze format, for computer-assisted determination of WMH volume. For each 
subject, the signal intensity threshold for WMH was manually edited and used to create a region-of-interest map 
of supratentorial WMHs. All measurements were performed independently by researchers who were blinded to 
clinical data.
Kidney function assessment. UACR was determined from the quantitative measures obtained for 
urinary albumin and creatinine excretion and then used as a parameter for kidney dysfunction. eGFR was 
calculated from the Modification of Diet in Renal Disease (MDRD) formula (GFR = 175 × serum creati-
nine−1.154 × age−0.203 × 0.742 [for females])12. Kidney function was categorized as normal (≥90) or mild dysfunc-
tion (60 to 89.9), moderate dysfunction (30 to 59.9), or severe dysfunction (<30 mL/min/1.73 m2)13.
statistical analysis. WMH volume data were extremely skewed to the left side. Consequently, these data 
needed to be transformed prior to analysis. Due to the large number of subjects with a WMH volume of zero 
(n = 537, 22.4%), we opted to treat WMH data by square root transformation ( WMH volume ).
At first, we performed univariate linear regression analyses to investigate the association between WMH vol-
ume and each of the baseline characteristics. Considering previous studies, and the established cardiovascular 
disease risk factors7–10,14,15, the following variables were included as cofactors for multivariate analyses: age, sex 
smoking, body mass index, hypertension, diabetes, dyslipidemia, and the use of anti-coagulation or anti-platelet 
drugs. Multivariate linear regression analysis was used to assess the association between UACR level and WMH 
volume. The natural logarithm of UACR data was used as an independent variable. Next, we used the same mul-
tivariate analysis to investigate categorical variables of kidney dysfunction. In model I, kidney function was cat-
egorized according to the level of albuminuria. Significant albuminuria was defined as when UACR was ≥0.0316. 
In model II, categorization of kidney function according to eGFR level was used as a predictor variable. As only 3 
(0.1%) had an eGFR < 30 ml/min/1.73 m2, we combined subjects with an eGFR < 30 and those with an eGFR of 
30–59.9 into the eGFR < 60 category. In model III, a combination of albuminuria and eGFR data was considered 
simultaneously. Kidney function was categorized as follows: 1) no significant albuminuria and an eGFR ≥ 60 
(reference group); 2) an eGFR < 60 only (without proteinuria); 3) significant albuminuria only (eGFR ≥ 60); and 
4) significant albuminuria and an eGFR < 60. To present volumetric differences across the kidney function cate-
gories in model III, we calculated adjusted means for the square root of WMH volumes. The calculated adjusted 
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means, and their confidence intervals, for the square root of WMH volume were then re-squared and Tukey’s post 
hoc analysis performed.
All statistical analyses were conducted using STATA software version 14.1 (StataCorp., TX) and p values less 
than 0.05 were considered statistically significant.
Results
Baseline characteristics and univariate analysis. The distribution of baseline characteristics is shown 
in Table 1. Mean WMH volume was 2.7 ± 6.0 cm3 and mean age was 56.9 ± 8.3 years. In total, 1,215 (55.2%) 
subjects were male. Mean systolic and diastolic blood pressures were 126.6 ± 15.8and 76.3 ± 10.6 mmHg, respec-
tively. Mean serum creatinine level was within normal range (0.92 mg/dL) and mean eGFR was 78.0 ± 14.8 ml/
min/1.73 m2. Mean UACR was 0.02 ± 0.10and 166 subjects (7.5%) showed significant albuminuria.
In our univariate analyses, we found that the following factors were significantly associated with a change 
in WMH volume: age, smoking habit, taking anti-hypertensive, anti-diabetic, anti-dyslipidemic drugs, 
anti-coagulation/anti-platelet drugs, systolic and diastolic blood pressure, eGFR, UACR, total cholesterol, low 
density lipoprotein, serum hemoglobin A1c level, hypertension, and diabetes (Table 2).
Association between kidney dysfunction and WMH volume. In our multivariate regression 
analysis, UACR was independently associated with a change in WMH volume (β = 0.113; p < 0.001) after 
adjustment for the above-mentioned demographic, lifestyle, and clinical factors (Table 3). Subjects with signif-
icant albuminuria (β = 0.163; p = 0.045) or moderate-to-severe kidney dysfunction (β = 0.219; p = 0.005) had 
a higher WMH volume. The association between eGFR < 60 only (without albuminuria) or significant albu-
minuria only (with normal eGFR) and WMH volume was not statistically significant. However, subjects with 
both significant albuminuria and an eGFR < 60 had a significantly higher WMH volume (β = 0.652; p < 0.001) 
(Table 4). The calculated WMH volume in subjects with both significant albuminuria and an eGFR < 60 (vol-
ume = 3.45 cm3; confidence interval (CI), 2.38 to 4.71) had more than twice the volume of WMH as did those 
White Matter Hyperintensity Volume - cm3 2.7 ±6.0
Age (year) 56.9 ±8.3
Male, n (%) 1,215 (55.2)
Current Smoker, n (%) 410 (18.6)
Taking Anti-hypertensive Drugs, n. (%) 551 (25.0)
Taking Anti-diabetic Drugs, n. (%) 154 (7.0)
Taking Anti-dyslipidemic Drugs, n (%) 177 (8.0)
Taking Anti-coagulation or Anti-platelet Drugs*, n (%) 224 (10.2)
Body Mass Index - kg/m2 24.1 ±3.0
Systolic Blood Pressure - mmHg 126.6 ±15.8
Diastolic Blood Pressure - mmHg 76.3 ±10.6
Creatinine - mg/dL 0.92 ±0.21
eGFR† - ml/min/1.73 m2 78.0 ±14.8
   ≥90 ml/min/1.73 m2, n (%) 421 (19.1)
   60–89.9 ml/min/1.73 m2, n (%) 1610 (73.1)
   30–59.9 ml/min/1.73 m2, n (%) 169 (7.7)
   <30 ml/min/1.73 m2, n (%) 3 (0.1)
Urine Albumin-to-Creatinine Ratio 0.02 ±0.10
   <0.03 2,037 (92.5)
   ≥0.03 166 (7.5)
Total Cholesterol - mg/dL 200.7 ±35.6
Low Density Lipoprotein - mg/dL 126.3 ±34.3
High Density Lipoprotein - mg/dL 54.5 ±13.7
Triglyceride - mg/dL 119.6 ±70.0
Hemoglobin A1c 5.92 ±0.78
Hypertension‡, n (%) 859 (39.0)
Diabetes§, n (%) 330 (15.0)
Dyslipidemia¶, n (%) 457 (20.7)
Table 1. Baseline characteristics of study subjects (N = 2,203) eGFR, estimated glomerular filtration rate. 
Values are shown as means ± standard deviation. *Subjects taking aspirin, plavix, warfarin, or other antiplatelet 
drugs. †Calculated using the Modification of Diet in Renal Disease formula. ‡Subjects taking antihypertensive 
drugs or with a SBP ≥ 140 mmHg, or a DBP ≥90 mmHg. §Subjects taking antidiabetic drugs or with a fasting 
blood glucose ≥ 126 mg/dL or a HbA1c ≥6.5%. ¶Subjects taking lipid lowering drugs or with a total cholesterol 
level ≥ 240 mg/dL.
4Scientific RepoRts |          (2019) 9:8596  | https://doi.org/10.1038/s41598-019-45109-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
in the other groups(for the normal group: volume = 1.45, CI, 1.35 to 1.56; for the eGFR < 60 only group: vol-
ume = 1.71 cm3,CI, 1.30 to 2.17;for the significant albuminuria only group: volume = 1.52, CI, 1.13 to 1.98) 
(Fig. 1).
Discussion
In this study, we investigated the association between kidney dysfunction, as defined by UACR and eGFR, and 
WMH volume in neurologically healthy adults encompassing a wide age range of subjects by using quantitative 
WMH volume data after adjustments for potential demographic, lifestyle, and clinical risk factors. We found that 
the presence and degree of kidney dysfunction, as defined by albuminuria and eGFR level, was independently 
associated with WMH volume.
Cerebral small vessel diseases including WMH are known to result from endothelial impairment and related 
vascular dysfunction17. In addition, subjects with kidney dysfunction are also known to be prone to such endothe-
lial damages and thromboembolic events6,18–20. As both WMH and kidney dysfunction share the pathophysiolog-
ical features21, the association between the impairments of these two end-organs was of great interest. Although a 
limited number of previous studies have dealt with kidney dysfunction and the volumetric degree of WMH, they 
had a variety of methodological limitations including relatively small sample size7,9, deviated age groups7,9, the 
use of simple grading methods for WMH volume such as measuring volume in a non-quantitative manner7,8, and 
bias-related log-transformation of WMH volume resulting in a large number of ‘zero’ values9,10.
The present study involved a large sample size and covered various age-groups. In total, 449 subjects (20.4%) 
were in their 40 s, while 960 (43.6%) were in their 50 s; none had any overt history of stroke. Furthermore, we 
measured WMH volume in a direct manner using a semi-automated method, which supports the reliability of 
the volumetric association between kidney dysfunction and WMH. Moreover, as we normalized the distribution 
of WMH volume using a square root transformation, possible bias related with ‘zero WMH’ value was avoided. 
These characteristics of the present study strongly support the generalizability of our results.
Consistent with previous studies, we found that kidney dysfunction was independently associated with 
WMH volume regardless of various confounding factors7–10. In addition, decreased eGFR and UACR seem to 
β (95% CI) P
Age 0.060 (0.055 to 0.065) <0.001
Male 0.038 (−0.055 to 0.131) 0.424
Current Smoker −0.196 (−0.315 to −0.077) 0.001
Taking Anti-hypertensive Drugs 0.402 (0.296 to 0.507) <0.001
Taking Anti-diabetic Drugs 0.403 (0.222 to 0.584) <0.001
Taking Anti-dyslipidemic Drugs 0.174 (0.003 to 0.344) 0.046
Taking Anti-coagulation or Anti-platelet Drugs* 0.309 (0.156 to 0.462) <0.001
Body Mass Index −0.010 (−0.026 to 0.005) 0.193
Systolic Blood Pressure 0.013 (0.010 to 0.016) <0.001
Diastolic Blood Pressure 0.011 (0.006 to 0.015) <0.001
Creatinine 0.409 (0.184 to 0.634) <0.001
eGFR† - ml/min/1.73 m2 −0.007 (−0.010 to −0.004) <0.001
   ≥90 ml/min/1.73 m2 - no. (%) reference
   60–89.9 ml/min/1.73 m2 - no. (%) 0.043 (−0.075 to 0.161) 0.471
   30–59.9 ml/min/1.73 m2 - no. (%) 0.499 (0.303 to 0.695) <0.001
   <30 ml/min/1.73 m2 - no. (%) 0.307 (1.825 to 4.320) <0.001
Urine Albumin/Creatinine Ratio‡ 0.231 (0.185 to 0.278) <0.001
   <0.03 reference
   ≥0.03 0.463 (0.288 to 0.637) <0.001
Total Cholesterol - mg/dL −0.001 (−0.003 to 0.000) 0.047
Low Density Lipoprotein - mg/dL −0.001 (−0.003 to 0.000) 0.041
High Density Lipoprotein - mg/dL −0.001 (−0.004 to 0.002) 0.558
Triglyceride - mg/dL 0.000 (−0.000 to 0.001) 0.297
Hemoglobin A1c - % 0.150 (0.091 to 0.210) <0.001
Hypertension§ 0.450 (0.357 to 0.543) <0.001
Diabetes¶ 0.406 (0.278 to 0.535) <0.001
Dyslipidemia** 0.042 (−0.072 to 0.156) 0.472
Table 2. Univariate Linear Regression Between White Matter Hyperintensity Volume and Potential Risk 
Factors. CI, confidence interval; eGFR, estimated glomerular filtration rate. *Those who were taking aspirin, 
clopidogrel, warfarin, or other antiplatelet drugs. †Calculated using the Modification of Diet in Renal Disease 
formula. ‡Natural logarithm of urine microalbumin/creatinine ratio. §Those who were taking antihypertensive 
drugs or SBP ≥ 140 mmHg, or DBP ≥ 90 mmHg. ¶Those who were taking antidiabetic drugs or fasting 
blood glucose ≥ 126 mg/dL or Hb A1c ≥ 6.5%. **Those who were taking lipid lowering drugs or total 
cholesterol ≥ 240 mg/dL.
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be synergistically associated with WMH volume. Conversely, the WMH volume was not significantly increased 
in subjects with isolated decreased eGFR or isolated UACR abnormality. The results could be explained based 
on transient conditions. Unfortunately, our study was based on tests performed at a single time point. Transient 
albuminuria can be shown in the normal population22. Especially, the overnight fasting condition in our study 
may have caused transient albuminuria or decreased eGFR by dehydration. However, in the cases with both albu-
minuria and decreased eGFR, we can assume the high possibility of it resulting from chronic kidney dysfunction 
or a more severe status. Since this chronic condition may affect the brain, it is understandable that subjects with 
both albuminuria and decreased eGFR had significantly larger WMH volumes22.
Systolic blood pressure and the use of antihypertensive medications were also significantly associated with 
WMH volume. As WMH is associated with overt stroke and related complications2–4, the reduction of blood pres-
sure in subjects with hypertension might be effective in both kidney protection and stoke prevention23. However, 
although the association between kidney dysfunction and WMH volume was independent of systolic blood pres-
sure or antihypertensive medication, it is still unclear whether kidney dysfunction and WMH volume are inde-
pendent concurrent impairments caused by hypertension or whether kidney dysfunction is an independent risk 
factor of WMH volume.
One notable limitation of the present study is its cross-sectional design that could not guarantee a causal 
relationship between risk factors and WMH volume. To partially address this limitation, we included various 
potential co-factors in our statistical analysis. However, the observational study design still made it impossible to 
assert a causal relationship. Longitudinal studies are now needed to address this issue. Another limitation is the 
possible selection bias caused by income status or health demands. The cost of the screening program including 
brain MRI is between $1,000 to $4,000 and is not covered by insurance. The participants of this study may have 
higher incomes or higher health demands that can justify the cost. However, we suggest that there was little 
difference between our participants and the general population since most participants had neither symptoms 
Changes in Square Root of 
WMH Volume (95% CI) P*
Urine Albumin-to-Creatinine Ratio† 0.113 (0.068 to 0.158) <0.001
Age 0.055 (0.050 to 0.061) <0.001
Sex (Male) 0.061 (−0.028 to 0.151) 0.180
Current Smoking 0.006 (−0.108 to 0.120) 0.919
BMI −0.013 (−0.027 to 0.001) 0.071
Hypertension 0.253 (0.164 to 0.642) <0.001
Diabetes 0.063 (−0.059 to 0.185) 0.314
Dyslipidemia −0.063 (−0.165 to 0.039) 0.228
Taking Anticoagulation or Anti-platelet Drugs‡ −0.054 (−0.193 to 0.086) 0.450
Table 3. Multivariate Linear Regression between White Matter Hyperintensity Volume and Potential Risk 
Factors. WMH, white matter hyperintensity; CI, confidence interval; eGFR, estimated glomerular filtration rate. 
*P values were calculated by multivariate linear regression analysis adjusted for age, sex, smoking, body mass 
index, hypertension, diabetes, dyslipidemia, and the use of anti-coagulation or anti-platelet drugs. †Natural 
logarithm of urine albumin-to-creatinine ratio. ‡Subjects taking aspirin, plavix, warfarin, or other antiplatelet 
drugs.
Changes in Square Root of WMH 
Volume (95% CI) P*
Model I (UACR)
   <0.03 Reference
   ≥0.03 0.163 (0.004 to 0.322) 0.045
Model II (eGFR)
   ≥60 Reference
   <60 0.219 (0.065 to 0.374) 0.005
Model III (UACR/eGFR)
   Negative (N = 1,903) Reference
   Only eGFR < 60 (N = 134) 0.102 (−0.071 to 0.275) 0.250
   Only UACR ≥0.03 (N = 128) 0.030 (−0.149 to 0.209) 0.745
  Both+ (N = 38) 0.652 (0.336 to 0.969) <0.001
Table 4. Changes in White Matter Hyperintensity Volume according to Kidney Functions Groups. WMH, 
white matter hyperintensity; UACR, urine albumin-to-creatinine ratio, CI, confidence interval; eGFR, estimated 
glomerular filtration rate. *P values were calculated by multivariate linear regression analysis adjusted for age, 
sex, smoking, body mass index, hypertension, diabetes, dyslipidemia, and the use of anti-coagulation or anti-
platelet drugs.
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nor prior diagnosis of brain lesions, and the prevalence of major comorbid conditions (hypertension, diabetes 
mellitus, and dyslipidemia) was similar to that of the general population in South Korea24. Similarly, participant 
selection bias for UACR may remain. Usually, more tests could be performed in the higher risk group. Indeed, 
there were statistical differences between subjects with and without UACR (Supplementary Table 1). However, 
subjects with UACR showed higher risk in several factors, such as systolic blood pressure, GFR, and hemoglobin 
A1c, and lower risk in other factors, such as age and fasting blood glucose level. We assume that the overall risk 
difference would not be large between both groups. Finally, kidney damage is defined by persistent albuminuria, 
while our study are limited to a single test. Future studies including repeated urine tests will be needed.
In conclusion, kidney dysfunction, as defined by albuminuria and eGFR, were independently associated with 
WMH volume in a neurologically healthy population of subjects undergoing routine health screening. Risk fac-
tors related to WMH and its detrimental outcomes should therefore be strictly modified in subjects with kidney 
dysfunction.
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